216 related articles for article (PubMed ID: 32686927)
1. An update on biological therapies for pediatric allergic diseases.
Castagnoli R; De Filippo M; Votto M; Marseglia A; Montagna L; Marseglia GL; Licari A
Minerva Pediatr; 2020 Oct; 72(5):364-371. PubMed ID: 32686927
[TBL] [Abstract][Full Text] [Related]
2. Biologics in Children with Allergic Diseases.
Licari A; Manti S; Marseglia A; De Filippo M; De Sando E; Foiadelli T; Marseglia GL
Curr Pediatr Rev; 2020; 16(2):140-147. PubMed ID: 31660839
[TBL] [Abstract][Full Text] [Related]
3. Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria.
Chiarella SE
Allergy Asthma Proc; 2019 Nov; 40(6):485-489. PubMed ID: 31690400
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of omalizumab in paediatric age: an update of literature data.
Matin N; Tabatabaie O; Falsaperla R; Pavone P; Serra A; Cocuzza S; Di Mauro P; Licciardello L; Lubrano R; Vitaliti G
J Biol Regul Homeost Agents; 2016; 30(2):579-84. PubMed ID: 27358151
[TBL] [Abstract][Full Text] [Related]
5. Current status of therapy with omalizumab in children.
Baena-Cagnani CE; Gómez RM
Curr Opin Allergy Clin Immunol; 2014 Apr; 14(2):149-54. PubMed ID: 24535142
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab : other indications and unanswered questions.
Mankad VS; Burks AW
Clin Rev Allergy Immunol; 2005 Aug; 29(1):17-30. PubMed ID: 16222081
[TBL] [Abstract][Full Text] [Related]
7. The use of anti-IgE therapy beyond allergic asthma.
Stokes JR; Casale TB
J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
[TBL] [Abstract][Full Text] [Related]
8. Real-life long-term omalizumab therapy in children with severe allergic asthma.
Deschildre A; Marguet C; Langlois C; Pin I; Rittié JL; Derelle J; Abou Taam R; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
Eur Respir J; 2015 Sep; 46(3):856-9. PubMed ID: 26022964
[No Abstract] [Full Text] [Related]
9. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
Chipps BE; Figliomeni M; Spector S
Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
[TBL] [Abstract][Full Text] [Related]
10. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
11. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.
Holm JG; Sørensen JA; Thomsen SF
Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086
[No Abstract] [Full Text] [Related]
12. Strategies for choosing a biologic for your patient with allergy or asthma.
Saco T; Ugalde IC; Cardet JC; Casale TB
Ann Allergy Asthma Immunol; 2021 Dec; 127(6):627-637. PubMed ID: 34642091
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
Nieto García A; Garriga-Baraut T; Plaza Martín AM; Nieto Cid M; Torres Borrego J; Folqué Giménez MDM; Lozano Blasco J; Bosque García M; Moreno-Galarraga L; Tortajada-Girbés M; Rivas Juesas C; Penín Antón M; Caballero-Rabasco MA; Gaboli M; López Neyra A; Navarro Morón J; Freixa Benavente A; Valdesoiro Navarrete L; Ballester Asensio E; Sanz Santiago V; Romero García R; Gimeno Díaz de Atauri Á; Valenzuela Soria A; Sánchez Mateos M; Batlles Garrido J; Andrés Martín A; Campos Alonso E; Aragón Fernández C; Vázquez Rodríguez E; Martínez Pardo L; Del-Río Camacho G; Mazón Ramos Á
Pediatr Allergy Immunol; 2021 Jul; 32(5):980-991. PubMed ID: 33619748
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Clinical Allergy and Immunology.
Simon D
Int Arch Allergy Immunol; 2018; 177(4):324-333. PubMed ID: 30399611
[TBL] [Abstract][Full Text] [Related]
15. Anti-IgE--emerging opportunities for Omalizumab.
Babu KS; Polosa R; Morjaria JB
Expert Opin Biol Ther; 2013 May; 13(5):765-77. PubMed ID: 23517576
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab in children.
Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab for treatment of refractory severe atopic dermatitis. A pediatric perspective.
Iannelli M; Caminiti L; Vaccaro M; Marafioti I; Spinuzza A; Panasiti I; Barbalace A; Crisafulli G; Pajno GB
Dermatol Ther; 2020 Jul; 33(4):e13519. PubMed ID: 32378300
[TBL] [Abstract][Full Text] [Related]
18. Biologics for Asthma and Allergic Skin Diseases in Children.
De Keyser HH; Chipps B; Dinakar C;
Pediatrics; 2021 Nov; 148(5):. PubMed ID: 34663682
[TBL] [Abstract][Full Text] [Related]
19. Exploration of the efficacy of anti-immunoglobulin E monoclonal antibodies in the treatment of allergic asthma.
Qian XJ; Hu XT; Jiang P
Immunology; 2023 May; 169(1):96-101. PubMed ID: 36424828
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab in children with severe allergic disease: a case series.
Crisafulli G; Caminiti L; Chiera F; Arasi S; Salzano G; Panasiti I; Barbalace A; Pajno GB
Ital J Pediatr; 2019 Jan; 45(1):13. PubMed ID: 30642367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
